Expanded Diversity, Enhanced Screening Power: WuXi Biology is pleased to introduce PeptideDEL 2.0, our upgraded DNA-encoded peptide library designed to...

Dear customers and friends, As 2025 comes to a close, I hope you and your family had a wonderful year!...

Making the ‘Impossible Triangle’ Possible at WuXi AppTec: “Every drug can be made and every disease can be treated.” Over...

How WuXi AppTec Aims to Catalyze Europe’s Biotech Transformation. In an exclusive interview, Dr. Steve Yang, co-CEO of WuXi AppTec,...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments to combat cancers and other conditions. In...

NMR is a benchmark tool for fragment-based drug design, offering quantitative binding data and detailed structural insights on target proteins....

Looking for a solution to accelerate your drug discovery processes? Introducing WuXi AppTec’s Integrated Direct-to-Biology (D2B) platform—a cost-effective and time-saving...

We are excited to announce the official launch of WuXi Biology HTS Platform 2.0, an advanced platform designed to enhance...

[Detection Antibodies + Target Development + High-Standard Controls] Empowering the Entire Drug Development Verification Process: In 2024 the OncoWuXi database...